Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 8/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.33 |
| ▸ | FAP | Q12884 | 3/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.33 |
| ▸ | PREP | P48147 | 2/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.33 |
| ▸ | PITRM1 | Q5JRX3 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8249586 | 0.86 | SLC7A5 (0.39) | SLC7A5DPP4ALOX5DPP7FAP | |
| SCHEMBL8295291 | 0.79 | TSHR (0.35) | ALOX5TSHR | |
| SCHEMBL769573 | 0.78 | SLC7A5 (0.48) | SLC7A5DPP4DPP7FAPDPP8 | |
| SCHEMBL769572 | 0.78 | SLC7A5 (0.48) | SLC7A5DPP4DPP7FAPDPP8 | |
| SCHEMBL84795 | 0.78 | SLC7A5 (0.48) | SLC7A5DPP4DPP7FAPDPP8 | |
| SCHEMBL8252018 | 0.77 | SLC7A5 (0.32) | SLC7A5DPP4ALOX5IDO1 | |
| Hydrochloric Acid SCHEMBL1456828 | 0.76 | SLC7A5 (0.46) | SLC7A5DPP4DPP7FAPDPP8 | |
| Hydrochloric Acid SCHEMBL17099133 | 0.76 | SLC7A5 (0.46) | SLC7A5DPP4DPP7FAPDPP8 | |
| SCHEMBL145865 | 0.73 | SLC7A5 (0.48) | SLC7A5DPP4DPP7FAPDPP8 | |
| SCHEMBL10873048 | 0.72 | CHRNB2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006130607-A2 | CONTROLLED-RELEASE FORMULATION USEFUL FOR TREATING DISORDERS ASSOCIATED WITH HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130687-A2 | LIVER/PLASMA CONCENTRATION RATIO FOR DOSING HEPATITIS C VIRUS PROTEASE INHIBITOR | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130553-A2 | HCV PROTEASE INHIBITORS | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130552-A2 | METHODS OF TREATING HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130628-A2 | COMBINATION OF HCV PROTEASE INHIBITORS WITH A SURFACTANT | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130688-A2 | COMPOUNDS FOR INHIBITING CATHEPSIN ACTIVITY | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130626-A2 | METHOD FOR MODULATING ACTIVITY OF HCV PROTEASE THROUGH USE OF A NOVEL HCV PROTEASE INHIBITOR TO REDUCE DURATION OF TREATMENT PERIOD | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130554-A2 | METHODS OF TREATING HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2005085275-A1 | INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | SCHERING CORPORATION (US) | 2005-09-15 | — | — | WO | disclosed |